- Home
- PNR vs NTRA Comparison
PNR vs NTRA Comparison
Compare PNR & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNR
- NTRA
- Stock Information
- Founded
- PNR 1966
- NTRA 2003
- Country
- PNR United Kingdom
- NTRA United States
- Employees
- PNR N/A
- NTRA N/A
- Industry
- PNR Industrial Machinery/Components
- NTRA Medical Specialities
- Sector
- PNR Industrials
- NTRA Health Care
- Exchange
- PNR Nasdaq
- NTRA Nasdaq
- Market Cap
- PNR 17.7B
- NTRA 18.4B
- IPO Year
- PNR N/A
- NTRA 2015
- Fundamental
- Price
- PNR $80.36
- NTRA $148.08
- Analyst Decision
- PNR Buy
- NTRA Strong Buy
- Analyst Count
- PNR 15
- NTRA 17
- Target Price
- PNR $110.00
- NTRA $176.65
- AVG Volume (30 Days)
- PNR 1.9M
- NTRA 1.6M
- Earning Date
- PNR 04-22-2025
- NTRA 05-08-2025
- Dividend Yield
- PNR 1.25%
- NTRA N/A
- EPS Growth
- PNR N/A
- NTRA N/A
- EPS
- PNR 3.74
- NTRA N/A
- Revenue
- PNR $4,082,800,000.00
- NTRA $1,696,911,000.00
- Revenue This Year
- PNR $2.31
- NTRA $15.33
- Revenue Next Year
- PNR $4.38
- NTRA $18.50
- P/E Ratio
- PNR $21.49
- NTRA N/A
- Revenue Growth
- PNR N/A
- NTRA 56.75
- 52 Week Low
- PNR $72.63
- NTRA $83.13
- 52 Week High
- PNR $110.71
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- PNR 40.30
- NTRA 50.83
- Support Level
- PNR $79.80
- NTRA $125.38
- Resistance Level
- PNR $83.83
- NTRA $152.66
- Average True Range (ATR)
- PNR 3.85
- NTRA 8.82
- MACD
- PNR 0.07
- NTRA 1.47
- Stochastic Oscillator
- PNR 40.09
- NTRA 82.19
About PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Pentair's business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2023.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.